Ewing's sarcoma is a malignant tumor, the second most common bone tumor in children and young adults. It mostly develops in bones, such as the femur, pelvis or ribs, but can also appear in soft tissues - such as muscle tissue. The peak incidence is between the ages of 15 and 19, although younger children are often affected. Unfortunately, more than half of patients also have metastatic lesions at the time of diagnosis. Therefore, it is important to diagnose quickly and implement appropriate treatment. However, about 20-30% of patients face treatment failure - in order to minimize this percentage, the Mother and Child Institute has launched Project BUTTERFLY, a study of a novel treatment method for Ewing's sarcoma patients.
Groundbreaking study
Project BUTTERFLY is one of the first immunotherapies in bone tumors and the first naxitamab therapy in Ewing's sarcoma worldwide. The trial aims to improve the diagnosis and treatment of patients with refractory and relapsed disease, as well as standardize and unify diagnostic and therapeutic approaches. It will also enable the creation of a biobank to store patients' biological samples. This, in turn, will help further the dev...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
